Notice for crizanlizumab (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
crizanlizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate solution for Infusion
Indication
For the prevention of vaso-occlusive crises in sickle cell disease patients
Therapeutic area
Haematology